Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim
Summary
Naarden, The Netherlands, 4 August 2022 Forbion, a leading European life sciences venture capital firm, today announces the $70 million financing of F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections with a high unmet medical need.Forbion, through its Forbion Growth Opportunities Fund II, co-led the $70 million round with Sofinnova Partners, alongside significant commitments from existing investors. F2G aims to file the first New Drug Application for olorofim in US by end of 2022.Francesco Maria Lavino, Chief Executive Officer of F2G, said: We are delighted to attract such high calibre of late-stage investors and additional capital to F2G. If approved, olorofim is expected to be the first new class of anti-fungal with differentiated mechanism of action in more than 20 years, with potential to make a real difference to patients and their families by saving lives and reducing disease burden in conditions with poor treatment options and high morbidity and mortality. For more information, please visit: www.forbion.comAbout F2G F2G is a biotech company with operations in the UK, US, and Austria focused on the discovery and development of novel therapies to treat potentially life-threatening invasive fungal infections. F2G is currently initiating a global Phase 3 trial (OASIS)2 to compare treatment with olorofim versus AmBisome\xae followed by standard of care (SOC) in patients with lower respiratory tract invasive fungal disease caused by proven or probable infection with Aspergillus species.